Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $25B in market capitalization, including over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc., where he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory and metabolic diseases, in addition to leadership of M&A, strategy, and biotherapeutics functions. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is currently the Principal and CEO of JMM Innovations, LLC, and a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, a Senior Advisor at Blackstone Life Sciences, and an Executive Partner at RTW Investments. He serves as a member of the Board of Directors of Beam Therapeutics, ProKidney Corp, and Takeda Pharmaceuticals, in addition to a number of privately held companies and non-profit organizations. Dr. Maraganore is Chair Emeritus for the Biotechnology Industry Organization (BIO), where he was Chair from 2017-2019.